小分子降解剂开发商PAQ Therapeutics宣布完成3900万美元B轮融资，并启动1期临床试验，推进针对高未满足需求的KRAS驱动癌症的新型疗法-动脉网

PAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet Need

CISION 等信源发布 2025-05-07 19:00



可切换为仅中文







--Series B co-led by MRL Ventures Fund (MRLV) and Bayland Capital, with participation from Johnson & Johnson Innovation – JJDC Inc., LAV Fund, BioTrack Capital, and Sherpa Health Partners--

--B轮融资由MRL Ventures Fund（MRLV）和Bayland Capital共同领投，Johnson & Johnson Innovation – JJDC Inc.、LAV Fund、BioTrack Capital和Sherpa Health Partners参与投资--

--First patient dosed in Phase 1 clinical study of lead candidate PT0253, a potent, selective KRAS G12D degrader--

--首个患者在领先候选药物PT0253的1期临床研究中接受给药，PT0253是一种强效、选择性的KRAS G12D降解剂--

BURLINGTON, Mass.

马萨诸塞州伯灵顿

，

May 7, 2025

2025年5月7日

/PRNewswire/ -- PAQ Therapeutics, a biotechnology company developing best- and first-in-class KRAS degraders for patients with lethal cancers lacking effective treatment options, today announced the completion of its

/PRNewswire/ -- PAQ Therapeutics是一家致力于为缺乏有效治疗选择的致命癌症患者开发同类最佳和首创KRAS降解剂的生物技术公司，今天宣布已完成其

$39 million

3900万美元

Series B funding. The Series B round was co-led by Bayland Capital and MRL Ventures Fund (MRLV), with participation from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), LAV Fund, BioTrack Capital, and existing investor Sherpa Health Partners.

B轮融资。B轮融资由Bayland Capital和MRL Ventures Fund（MRLV）共同领投，参与者包括强生创新部门（Johnson & Johnson Innovation – JJDC, Inc.，简称JJDC）、LAV基金、BioTrack资本以及现有投资者Sherpa Health Partners。

The capital raised will fund PAQ's next stage of clinical development for the company's lead asset PT0253, a potent and selective degrader of KRAS G12D, a known driver for a range of solid tumors. PT0253 has demonstrated best-in-class potential based on preclinical comparison to existing agents currently in clinical development targeting the same KRAS mutant.

筹集的资金将用于PAQ公司主要资产PT0253的下一阶段临床开发，这是一种强效且选择性的KRAS G12D降解剂，KRAS G12D是多种实体瘤的已知驱动因素。基于与目前针对相同KRAS突变体正在进行临床开发的现有药物的临床前对比，PT0253已显示出同类最佳的潜力。

In Q1 2025, the first patient was dosed in a Phase 1 study to assess its safety and tolerability..

2025年第一季度，第一名患者在一期研究中接受给药，以评估其安全性和耐受性。

'The successful completion of our Series B funding and rapid enrollment of our Phase 1 trial in the US for PT0253 mark significant steps forward in our clinical development efforts,' said

“我们B轮融资的成功完成以及PT0253在美国的1期试验的快速招募，标志着我们在临床开发工作上迈出了重要的步伐，”

Nan Ji

南极

, PhD, PAQ's co-founder, President, and CEO. 'The strong support from our investors validates the potential of our innovative approach. We now turn our focus to executing a robust clinical development plan while continuing to develop a differentiated pipeline of KRAS degraders.'

，博士，PAQ的联合创始人、总裁兼首席执行官。“我们投资者的大力支持验证了我们创新方法的潜力。我们现在将重点转向执行一项强有力的临床开发计划，同时继续开发差异化的KRAS降解剂管道。”

The funds will also support the advancement of the company's second asset through IND-enabling studies.

这笔资金还将支持公司第二个资产通过新药临床试验申请（IND）的研究。

'PAQ represents a compelling opportunity to develop transformative therapies for oncology populations with high unmet need,' said Olga Danilchanka, Partner, MRLV, the therapeutics-focused corporate venture arm of Merck & Co. 'Their innovative efforts advancing the targeted protein degradation modality aligns with our commitment to backing scientifically rigorous teams that tackle pressing medical challenges.

“PAQ 代表了一个令人信服的机会，可以为具有高度未满足需求的肿瘤患者群体制定变革性疗法，”默克公司（Merck & Co.）旗下专注于治疗学的企业风险投资部门 MRLV 合伙人奥尔加·达尼尔琴科 (Olga Danilchanka) 表示。“他们在推进靶向蛋白降解模式方面的创新努力，与我们支持应对紧迫医学挑战的科学严谨团队的承诺高度一致。”

We're confident in PAQ's ability to unlock the full potential of KRAS degraders and are proud to support their journey toward achieving clinical impact.'.

我们相信PAQ有能力充分释放KRAS降解剂的潜力，并为支持他们实现临床影响的旅程感到自豪。

'The team at PAQ is at the forefront of an innovative approach to treat some of the most underserved patient populations in oncology,' said

“PAQ团队正处于一种创新方法的前沿，旨在治疗肿瘤学中一些最受忽视的患者群体，”

Yuexing Su

苏跃兴

, Founding Partner, Bayland Capital. 'We were attracted to PAQ based on its scientific approach, preclinical data, and experienced leadership team. We believe there is tremendous potential for KRAS degraders and are excited to be part of PAQ's next stage of growth.'

创始合伙人，Bayland Capital。 “我们被PAQ的科学方法、临床前数据和经验丰富的领导团队所吸引。我们相信KRAS降解剂具有巨大的潜力，并且很高兴能成为PAQ下一阶段增长的一部分。”

PAQ Therapeutics was founded in 2020 and completed a

PAQ Therapeutics 成立于2020年，并完成了

$30M

3000万美元

Series A financing in 2021. Over the last three years, the PAQ team gained proprietary understanding of KRAS biology, which guided medicinal chemistry to identify KRAS degraders. These programs have the potential to address key limitations of clinical-stage KRAS inhibitors, offering more effective and durable treatments..

2021年A轮融资。在过去的三年里，PAQ团队获得了对KRAS生物学的独家理解，这指导了药物化学识别KRAS降解剂。这些项目有潜力解决临床阶段KRAS抑制剂的关键局限性，提供更有效和持久的治疗方案。

About PAQ Therapeutics

关于PAQ Therapeutics

PAQ Therapeutics is a clinical-stage biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.

PAQ Therapeutics是一家临床阶段的生物技术公司，致力于开发针对致命癌症的最佳和首创KRAS降解剂，这些癌症目前缺乏有效的治疗选择。

Media Contact:

媒体联系人:

Peg Rusconi

佩格·鲁斯科尼

, Deerfield Group

，鹿场集团

Peg.Rusconi@deerfieldgroup.com

佩格·鲁斯科尼@deerfieldgroup.com

SOURCE PAQ Therapeutics

源PAQ治疗公司

WANT YOUR COMPANY'S NEWS